Omeros (FRA:3O8) Debt-to-Equity : -9.47 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Debt-to-Equity?

Omeros's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.73 Mil. Omeros's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €212.10 Mil. Omeros's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-22.91 Mil. Omeros's debt to equity for the quarter that ended in Dec. 2023 was -9.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Omeros's Debt-to-Equity or its related term are showing as below:

FRA:3O8' s Debt-to-Equity Range Over the Past 10 Years
Min: -30.07 Med: -1.84 Max: 14.63
Current: -9.47

During the past 13 years, the highest Debt-to-Equity Ratio of Omeros was 14.63. The lowest was -30.07. And the median was -1.84.

FRA:3O8's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs FRA:3O8: -9.47

Omeros Debt-to-Equity Historical Data

The historical data trend for Omeros's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Debt-to-Equity Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.78

-2.23

14.63

3.99

-9.47

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															3.99	6.22	16.64	-24.43	-9.47

Competitive Comparison of Omeros's Debt-to-Equity

For the Biotechnology subindustry, Omeros's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Omeros's Debt-to-Equity falls into.

Omeros Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Omeros's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.732	+	212.1)	/	-22.909
	=	-9.46

Omeros's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.732	+	212.1)	/	-22.909
	=	-9.46

Omeros (FRA:3O8) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Omeros Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Omeros's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines